<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858116</url>
  </required_header>
  <id_info>
    <org_study_id>ABY-025-MI105</org_study_id>
    <secondary_id>2012-005228-14</secondary_id>
    <nct_id>NCT01858116</nct_id>
  </id_info>
  <brief_title>PET Study of Breast Cancer Patients Using [68Ga]ABY-025</brief_title>
  <official_title>An Exploratory Study to Evaluate [68Ga]ABY-025 for PET Imaging of HER2 Expression in Subjects With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomedical Radiation Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affibody</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomedical Radiation Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate [68Ga]ABY-025 for PET imaging of HER2 expression in subjects with&#xD;
      HER2-positive or HER2-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-labeled, exploratory, single center study.&#xD;
&#xD;
        1. Group 1 (dose-finding) Six subjects with HER2-positive primary tumor status and four&#xD;
           subjects with HER2-negative status. [68Ga]ABY-025 PET with low dose (100 μg) of ABY-025&#xD;
           peptide is performed, followed by a repeated PET within three weeks using high dose (500&#xD;
           μg) ABY-025 peptide (radioactivity maximum 500 MBq). A third [68Ga]ABY-025 PET will be&#xD;
           performed in the HER2-positive subgroup only, when signs of progressive disease are&#xD;
           found at routine clinical evaluation or else latest after 12 months regardless of&#xD;
           disease status, then using the ABY-025 peptide dose previously determined to be&#xD;
           preferable.&#xD;
&#xD;
        2. Group 2 Ten subjects with HER2-positive primary tumor status. [68Ga]ABY-025 PET is&#xD;
           performed using the ABY-025 peptide dose determined to be preferable during the&#xD;
           dose-finding part of the study, followed by a second [68Ga]ABY-025 PET investigation at&#xD;
           signs of progressive disease or else latest after 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET image analysis: Standardized Uptake Value (SUV) and uptake kinetics of [68Ga]ABY-025 in breast cancer lesions and normal tissues</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SUV in metastases where biopsy results with HER2 status by IHC/FISH are available</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUV for each measured lesion, and appearance or disappearance of lesions, after progression or 9-12 months therapy</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUV for each measured lesion and number of detectable lesions, obtained with a low (100 μg) or high (500 μg) injected amount of ABY-025 peptide in the same subject</measure>
    <time_frame>Day 0 &amp; 1-3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUVs for all measured lesions obtained with a low (100 μg) or high (500 μg) injected where biopsy results with HER2 status by IHC and FISH are available</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Day 0 to 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody assay at 3 and 6 weeks</measure>
    <time_frame>Day 0 to 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood radioactivity kinetics and dosimetry of [68Ga]ABY-025</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of [68Ga]ABY-025 coinciding with metastatic lesions visible on [18F]FDG PET and focal uptake in regions without pathological findings on [18F]FDG PET</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>[68Ga]ABY-025</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]ABY-025</intervention_name>
    <description>Intravenous injection followed by PET imaging</description>
    <arm_group_label>[68Ga]ABY-025</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is &gt; 18 years of age&#xD;
&#xD;
          2. Diagnosis of invasive breast cancer with metastases&#xD;
&#xD;
          3. Availability of results from HER2 status previously determined on material from the&#xD;
             primary tumor, either&#xD;
&#xD;
               1. HER2-positive, defined as a DAKO HercepTest™ score of 3+ or FISH positive or&#xD;
&#xD;
               2. HER2-negative, defined as a DAKO HercepTest™ score of 0 or 1+ or else; if 2+ then&#xD;
                  FISH negative&#xD;
&#xD;
          4. Volumetrically quantifiable metastasis lesions on CT or MRI, with at least one lesion&#xD;
             &gt;= 10 mm in smallest diameter and suitable for biopsy&#xD;
&#xD;
          5. ECOG performance status of =&lt; 2&#xD;
&#xD;
          6. Life expectancy of at least 12 weeks&#xD;
&#xD;
          7. Hematological, liver and renal function test results within the following limits:&#xD;
&#xD;
             White blood cell count: &gt; 2.0 x 10^9/L Haemoglobin: &gt; 80 g/L Platelets: &gt; 50.0 x&#xD;
             10^9/L ALT, ALP, AST: =&lt; 5.0 times Upper Limit of Normal Bilirubin =&lt; 2.0 times Upper&#xD;
             Limit of Normal Serum creatinine: Within Normal Limits or else normal clearance&#xD;
&#xD;
          8. A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at&#xD;
             screening for all female patients of childbearing potential, who must use a medically&#xD;
             acceptable form of contraception from study start until at least 30 days after study&#xD;
             termination&#xD;
&#xD;
          9. Subject is able to participate in the diagnostic investigations to be performed in the&#xD;
             study&#xD;
&#xD;
         10. Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Manifest second, non-breast malignancy&#xD;
&#xD;
          2. Known HIV positive or chronically active hepatitis B or C&#xD;
&#xD;
          3. Administration of other investigational medicinal product within 30 days of screening&#xD;
&#xD;
          4. Ongoing toxicity &gt; grade 2 from previous standard or investigational therapies,&#xD;
             according to US National Cancer Institute's &quot;Common Terminology Criteria for Adverse&#xD;
             Events v4.0 [CTCAE]&quot;&#xD;
&#xD;
          5. Other ongoing severe disease that may influence the patient's ability to participate&#xD;
             in the study&#xD;
&#xD;
          6. Pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Lindman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital, Department of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>January 12, 2015</last_update_submitted>
  <last_update_submitted_qc>January 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Henrik Lindman, Oncology</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

